Vanderbilt Cardio-Oncology Archive — Page 1 of 1

February 21, 2019

AHA statement supports vascular cardio-oncology

The American Heart Association (AHA) has issued a scientific statement calling for the integration of cardio-oncology and vascular medicine to provide cancer patients and cancer survivors with optimal cardiovascular care.

By Tom Wilemon
November 15, 2018

Immunotherapies linked to specific heart complications

In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.

By Tom Wilemon
October 27, 2016

Emerging field of cardio-oncology seeks better tools

Improved therapies have led to a spike in the number of people living with cancer, and today there are more than 15.5 million survivors in the United States. However, some of these therapies can cause toxicities to the heart, the vessels and the body’s metabolism.

By Vanderbilt Health News
older man
February 4, 2016

Prostate cancer survivors’ risk of heart disease studied

The 3 million prostate cancer survivors in the United States are likely to die from something other than cancer, thanks to early detection, effective treatment and the disease’s slow progression.

By Kathy Whitney
October 15, 2015

VUMC set to host inaugural Global Cardio-Oncology Summit

Vanderbilt University Medical Center is hosting the first Global Cardio-Oncology Summit on Oct. 15-16, at the Hilton Nashville. The summit models a leading edge, interdisciplinary approach to cardio-oncology.

By Kathy Whitney
September 24, 2015

Cancer therapies’ impact on heart, kidneys explored

Vanderbilt is embarking on a multi-disciplinary approach to understand how promising cancer treatments, specifically certain kinase inhibitors, affect the heart and kidneys.

By Kathy Whitney